Pub. Date : 2014
PMID : 25116336
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 2 | Previously, we found that arsenic trioxide (ATO), a drug for acute promyelocytic leukemia, degrades mutant p53 protein through a proteasome pathway. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 3 | Previously, we found that arsenic trioxide (ATO), a drug for acute promyelocytic leukemia, degrades mutant p53 protein through a proteasome pathway. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 4 | We also found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, ATO-induced degradation of mutant p53 protein. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 5 | Interestingly, we found that ATO cooperates with HSP90 or HDAC inhibitor to promote mutant p53 degradation and growth suppression in tumor cells. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |
| 6 | Together, these data suggest that ATO promotes mutant p53 degradation in part via induction of the Pirh2-dependent proteasome pathway. | Arsenic Trioxide | tumor protein p53 | Homo sapiens |